According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion ...
Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the ...
Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The treatment is designed to be ...
FORT MYERS, Fla., Sept. 22, 2025 /PRNewswire/ -- Leveraging its proprietary real-world data, Florida Cancer Specialists & Research Institute, LLC (FCS) has concluded the first study to evaluate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results